{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:13:45Z","timestamp":1783692825008,"version":"3.55.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40262-024-01469-x","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T02:52:24Z","timestamp":1736218344000},"page":"257-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Physiologically Based Pharmacokinetic Model of Cefotaxime in Patients with Impaired Renal Function"],"prefix":"10.1007","volume":"64","author":[{"given":"Fatima","family":"Zbib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anth\u00e9a","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Velly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Blin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8344-412X","authenticated-orcid":false,"given":"Romain","family":"Guilhaumou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Gattacceca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"issue":"3","key":"1469_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2165\/00003495-198325030-00001","volume":"25","author":"AA Carmine","year":"1983","unstructured":"Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1983;25(3):223\u201389. https:\/\/doi.org\/10.2165\/00003495-198325030-00001.","journal-title":"Drugs"},{"issue":"4","key":"1469_CR2","doi-asserted-by":"publisher","first-page":"608","DOI":"10.2165\/00003495-199040040-00008","volume":"40","author":"PA Todd","year":"1990","unstructured":"Todd PA, Brogden RN. Cefotaxime. An update of its pharmacology and therapeutic use. Drugs. 1990;40(4):608\u201351. https:\/\/doi.org\/10.2165\/00003495-199040040-00008.","journal-title":"Drugs"},{"key":"1469_CR3","unstructured":"WHO. Model list of essential medicines. 2023. https:\/\/www.who.int\/groups\/expert-committee-on-selection-and-use-of-essential-medicines\/essential-medicines-lists. Accessed 25 Sep 2023."},{"key":"1469_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.18433\/J3CK88","volume":"20","author":"M Arafat","year":"2017","unstructured":"Arafat M, Kirchhoefer C, Mikov M, Sarfraz M, L\u00f6benberg R. Nanosized liposomes containing bile salt: a vesicular nanocarrier for enhancing oral bioavailability of BCS class III drug. J Pharm Pharm Sci. 2017;20:305\u201318. https:\/\/doi.org\/10.18433\/J3CK88.","journal-title":"J Pharm Pharm Sci"},{"issue":"Suppl A","key":"1469_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/jac\/6.suppl_a.83","volume":"6","author":"F Esmieu","year":"1980","unstructured":"Esmieu F, Guibert J, Rosenkilde HC, Ho I, Le Go A. Pharmacokinetics of cefotaxime in normal human volunteers. J Antimicrob Chemother. 1980;6(Suppl A):83\u201392. https:\/\/doi.org\/10.1093\/jac\/6.suppl_a.83.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl","key":"1469_CR6","doi-asserted-by":"publisher","first-page":"S333","DOI":"10.1093\/clinids\/4.supplement_2.s333","volume":"4","author":"JT Doluisio","year":"1982","unstructured":"Doluisio JT. Clinical pharmacokinetics of cefotaxime in patients with normal and reduced renal function. Rev Infect Dis. 1982;4(Suppl):S333\u201345. https:\/\/doi.org\/10.1093\/clinids\/4.supplement_2.s333.","journal-title":"Rev Infect Dis"},{"issue":"Suppl 2","key":"1469_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00003495-198700342-00008","volume":"34","author":"T Bergan","year":"1987","unstructured":"Bergan T. Pharmacokinetic properties of the cephalosporins. Drugs. 1987;34(Suppl 2):89\u2013104. https:\/\/doi.org\/10.2165\/00003495-198700342-00008.","journal-title":"Drugs"},{"key":"1469_CR8","unstructured":"Claforan\u00ae (Cefotaxime) Product Monograph. Sanofi-aventis Canada Inc. https:\/\/products.sanofi.ca\/en\/claforan.pdf. Revised November 12, 2014. Accessed 10 Apr 2023."},{"issue":"Suppl A","key":"1469_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/jac\/6.suppl_a.93","volume":"6","author":"DS Reeves","year":"1980","unstructured":"Reeves DS, White LO, Holt HA, Bahari D, Bywater MJ, Bax RP. Human metabolism of cefotaxime. J Antimicrob Chemother. 1980;6(Suppl A):93\u2013101. https:\/\/doi.org\/10.1093\/jac\/6.suppl_a.93.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl","key":"1469_CR10","doi-asserted-by":"publisher","first-page":"S366","DOI":"10.1093\/clinids\/4.supplement_2.s366","volume":"4","author":"RN Jones","year":"1982","unstructured":"Jones RN, Barry AL, Thornsberry C. Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy. Rev Infect Dis. 1982;4(Suppl):S366\u201373. https:\/\/doi.org\/10.1093\/clinids\/4.supplement_2.s366.","journal-title":"Rev Infect Dis"},{"issue":"Suppl A","key":"1469_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/jac\/6.suppl_a.69","volume":"6","author":"J Chamberlain","year":"1980","unstructured":"Chamberlain J, Coombes JD, Dell D, Fromson JM, Ings RJ, Macdonald CM, McEwen J. Metabolism of cefotaxime in animals and man. J Antimicrob Chemother. 1980;6(Suppl A):69\u201378. https:\/\/doi.org\/10.1093\/jac\/6.suppl_a.69.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1469_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/BF01647231","volume":"15","author":"F Jehl","year":"1987","unstructured":"Jehl F, Peter JD, Picard A, Dupeyron JP, Marescaux J, Sibilly A, Monteil H. Investigation of the biliary clearances of cefotaxime and desacetylcefotaxime by an original procedure in cholecystectomised patients. Infection. 1987;15(6):450\u20134. https:\/\/doi.org\/10.1007\/BF01647231.","journal-title":"Infection"},{"issue":"8","key":"1469_CR13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40262-017-0506-8","volume":"56","author":"A Ivanyuk","year":"2017","unstructured":"Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017;56(8):825\u201392. https:\/\/doi.org\/10.1007\/s40262-017-0506-8.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1469_CR14","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.idc.2009.06.008","volume":"23","author":"ME Levison","year":"2009","unstructured":"Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am. 2009;23(4):791\u2013815, vii. https:\/\/doi.org\/10.1016\/j.idc.2009.06.008.","journal-title":"Infect Dis Clin North Am"},{"issue":"Suppl A","key":"1469_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/jac\/6.suppl_a.103","volume":"6","author":"JP Fillastre","year":"1980","unstructured":"Fillastre JP, Leroy A, Humbert G, Godin M. Pharmacokinetics of cefotaxime in subjects with normal and impaired renal function. J Antimicrob Chemother. 1980;6(Suppl A):103\u201311. https:\/\/doi.org\/10.1093\/jac\/6.suppl_a.103.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1469_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000238166","volume":"29","author":"M Ohkawa","year":"1983","unstructured":"Ohkawa M, Okasho A, Motoi I, Tokunaga S, Shoda R, Kawaguchi S, Sawaki M, Shimamura M, Hirano S, Kuroda K, Awazu S. Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis. Chemotherapy. 1983;29(1):4\u201312. https:\/\/doi.org\/10.1159\/000238166.","journal-title":"Chemotherapy"},{"issue":"10302","key":"1469_CR17","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","volume":"398","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786\u2013802. https:\/\/doi.org\/10.1016\/S0140-6736(21)00519-5. (Epub 2021 Jun 24).","journal-title":"Lancet"},{"issue":"1","key":"1469_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003. (Epub 2022 Mar 18).","journal-title":"Kidney Int Suppl (2011)."},{"key":"1469_CR19","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1\u2013150. https:\/\/kdigo.org\/wp-content\/uploads\/2017\/02\/KDIGO_2012_CKD_GL.pdf. Accessed 25 Sep 2023."},{"issue":"7","key":"1469_CR20","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/ph17070924","volume":"17","author":"M Pasha","year":"2024","unstructured":"Pasha M, Zamir A, Rasool MF, Saeed H, Ahmad T, Alqahtani NS, Alqahtani LS, Alqahtani F. A comprehensive physiologically based pharmacokinetic model for predicting vildagliptin pharmacokinetics: insights into dosing in renal impairment. Pharmaceuticals (Basel). 2024;17(7):924.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"1469_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10928-016-9492-y","volume":"43","author":"C Hartmanshenn","year":"2016","unstructured":"Hartmanshenn C, Scherholz M, Androulakis IP. Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine. J Pharmacokinet Pharmacodyn. 2016;43(5):481\u2013504. https:\/\/doi.org\/10.1007\/s10928-016-9492-y. (Epub 2016 Sep 19).","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"1469_CR22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.apsb.2016.04.004","volume":"6","author":"X Zhuang","year":"2016","unstructured":"Zhuang X, Lu C. PBPK modeling and simulation in drug research and development. Acta Pharm Sin B. 2016;6(5):430\u201340. https:\/\/doi.org\/10.1016\/j.apsb.2016.04.004. (Epub 2016 Jun 23).","journal-title":"Acta Pharm Sin B."},{"issue":"11","key":"1469_CR23","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40262-019-00790-0","volume":"58","author":"SA Peters","year":"2019","unstructured":"Peters SA, Dolgos H. Requirements to establishing confidence in physiologically based pharmacokinetic (PBPK) models and overcoming some of the challenges to meeting them. Clin Pharmacokinet. 2019;58(11):1355\u201371. https:\/\/doi.org\/10.1007\/s40262-019-00790-0.","journal-title":"Clin Pharmacokinet"},{"key":"1469_CR24","unstructured":"Li Q, Guan Y, Xia C, Wu L, Zhang H, Wang Y. Physiologically-based pharmacokinetic modeling and dosing optimization of cefotaxime in preterm and term neonates. J Pharm Sci. 2024. S0022-3549(24)00086-8. (Epub ahead of print)."},{"issue":"Suppl A","key":"1469_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/jac\/6.suppl_a.219","volume":"6","author":"WM Gl\u00f6ckner","year":"1980","unstructured":"Gl\u00f6ckner WM, H\u00f6ffler U, Kindler J, Peters G, Sieberth HG. Elimination kinetics of cefotaxime in patients with renal insufficiency requiring dialysis. J Antimicrob Chemother. 1980;6(Suppl A):219\u201323. https:\/\/doi.org\/10.1093\/jac\/6.suppl_a.219.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1469_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1128\/AAC.18.3.369","volume":"18","author":"R Wise","year":"1980","unstructured":"Wise R, Baker S, Livingston R. Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels. Antimicrob Agents Chemother. 1980;18(3):369\u201371. https:\/\/doi.org\/10.1128\/AAC.18.3.369.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1469_CR27","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1128\/AAC.20.5.567","volume":"20","author":"R L\u00fcthy","year":"1981","unstructured":"L\u00fcthy R, Blaser J, Bonetti A, Simmen H, Wise R, Siegenthaler W. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother. 1981;20(5):567\u201375. https:\/\/doi.org\/10.1128\/AAC.20.5.567.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl B","key":"1469_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/jac\/8.suppl_b.263","volume":"8","author":"SM Harding","year":"1981","unstructured":"Harding SM, Monro AJ, Thornton JE, Ayrton J, Hogg MI. The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. J Antimicrob Chemother. 1981;8(Suppl B):263\u201372. https:\/\/doi.org\/10.1093\/jac\/8.suppl_b.263.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1469_CR29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1128\/AAC.23.3.429","volume":"23","author":"B Kemmerich","year":"1983","unstructured":"Kemmerich B, Lode H, Belmega G, Jendroschek T, Borner K, Koeppe P. Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother. 1983;23(3):429\u201334. https:\/\/doi.org\/10.1128\/AAC.23.3.429.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1469_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF01059394","volume":"13","author":"RM Ings","year":"1985","unstructured":"Ings RM, Reeves DS, White LO, Bax RP, Bywater MJ, Holt HA. The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. J Pharmacokinet Biopharm. 1985;13(2):121\u201342. https:\/\/doi.org\/10.1007\/BF01059394.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"6","key":"1469_CR31","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/BF00637745","volume":"36","author":"L Hary","year":"1989","unstructured":"Hary L, Andrejak M, Leleu S, Orfila J, Capron JP. The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites. Eur J Clin Pharmacol. 1989;36(6):613\u20136. https:\/\/doi.org\/10.1007\/BF00637745.","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl","key":"1469_CR32","doi-asserted-by":"publisher","first-page":"S379","DOI":"10.1093\/clinids\/4.supplement_2.s379","volume":"4","author":"RM Ings","year":"1982","unstructured":"Ings RM, Fillastre JP, Godin M, Leroy A, Humbert G. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. Rev Infect Dis. 1982;4(Suppl):S379\u201391. https:\/\/doi.org\/10.1093\/clinids\/4.supplement_2.s379.","journal-title":"Rev Infect Dis"},{"issue":"1","key":"1469_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/clpt.1985.130","volume":"38","author":"GR Matzke","year":"1985","unstructured":"Matzke GR, Abraham PA, Halstenson CE, Keane WF. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther. 1985;38(1):31\u20136. https:\/\/doi.org\/10.1038\/clpt.1985.130.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1469_CR34","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/cpt.2243","volume":"110","author":"K Rowland Yeo","year":"2021","unstructured":"Rowland Yeo K, Gil BE. An integrated approach for assessing the impact of renal impairment on pharmacokinetics of drugs in development: pivotal role of PBPK modelling. Clin Pharmacol Ther. 2021;110(5):1168\u201371.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1469_CR35","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3390\/antibiotics12081289","volume":"12","author":"R Guilhaumou","year":"2023","unstructured":"Guilhaumou R, Chevrier C, Setti JL, Jouve E, Marsot A, Julian N, Blin O, Simeone P, Lagier D, Mokart D, Bruder N, Garnier M, Velly L. \u03b2-Lactam pharmacokinetic\/pharmacodynamic target attainment in Intensive Care Unit patients: a prospective, observational, cohort study. Antibiotics (Basel). 2023;12(8):1289. https:\/\/doi.org\/10.3390\/antibiotics12081289.","journal-title":"Antibiotics (Basel)."},{"issue":"12","key":"1469_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.723731","volume":"2","author":"Y Luo","year":"2021","unstructured":"Luo Y, Wang Y, Ma Y, Wang P, Zhong J, Chu Y. Augmented renal clearance: what have we known and what will we do? Front Pharmacol. 2021;2(12): 723731. https:\/\/doi.org\/10.3389\/fphar.2021.723731.","journal-title":"Front Pharmacol"},{"issue":"12","key":"1469_CR37","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s11095-020-02964-z","volume":"37","author":"H Britz","year":"2020","unstructured":"Britz H, Hanke N, Taub ME, Wang T, Prasad B, Fernandez \u00c9, Stopfer P, Nock V, Lehr T. Physiologically based pharmacokinetic models of probenecid and furosemide to predict transporter mediated drug\u2013drug interactions. Pharm Res. 2020;37(12):250. https:\/\/doi.org\/10.1007\/s11095-020-02964-z.","journal-title":"Pharm Res"},{"issue":"Suppl B","key":"1469_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/jac\/14.suppl_b.143","volume":"14","author":"W Graninger","year":"1984","unstructured":"Graninger W, Uihlein M, Ferenci P, Moser C, Georgopoulos A. Cefotaxime and desacetyl-cefotaxime blood levels in hepatic dysfunction. J Antimicrob Chemother. 1984;14(Suppl B):143\u20136. https:\/\/doi.org\/10.1093\/jac\/14.suppl_b.143.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"1469_CR39","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1002\/jcph.1713","volume":"60","author":"PRV Malik","year":"2020","unstructured":"Malik PRV, Yeung CHT, Ismaeil S, Advani U, Djie S, Edginton AN. A physiological approach to pharmacokinetics in chronic kidney disease. J Clin Pharmacol. 2020;60(Suppl 1):S52\u201362. https:\/\/doi.org\/10.1002\/jcph.1713.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1469_CR40","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1208\/s12248-014-9626-3","volume":"16","author":"H Sayama","year":"2014","unstructured":"Sayama H, Takubo H, Komura H, Kogayu M, Iwaki M. Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients. AAPS J. 2014;16(5):1018\u201328. https:\/\/doi.org\/10.1208\/s12248-014-9626-3. (Epub 2014 Jun 11).","journal-title":"AAPS J"},{"issue":"12","key":"1469_CR41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/psp4.12566","volume":"9","author":"H Takita","year":"2020","unstructured":"Takita H, Scotcher D, Chinnadurai R, Kalra PA, Galetin A. Physiologically-based pharmacokinetic modelling of creatinine-drug interactions in the chronic kidney disease population. CPT Pharmacometr Syst Pharmacol. 2020;9(12):695\u2013706. https:\/\/doi.org\/10.1002\/psp4.12566. (Epub 2020 Nov 23).","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"2","key":"1469_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00228-018-2572-8","volume":"75","author":"S Pradhan","year":"2019","unstructured":"Pradhan S, Duffull SB, Walker RJ, Wright DFB. The intact nephron hypothesis as a model for renal drug handling. Eur J Clin Pharmacol. 2019;75(2):147\u201356. https:\/\/doi.org\/10.1007\/s00228-018-2572-8. (Epub 2018 Oct 8).","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"1469_CR43","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s40262-022-01121-6","volume":"61","author":"S Dubinsky","year":"2022","unstructured":"Dubinsky S, Malik P, Hajducek DM, Edginton A. Determining the effects of chronic kidney disease on organic anion transporter1\/3 activity through physiologically based pharmacokinetic modeling. Clin Pharmacokinet. 2022;61(7):997\u20131012. https:\/\/doi.org\/10.1007\/s40262-022-01121-6. (Epub 2022 May 5).","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1469_CR44","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1021\/acs.molpharmaceut.6b00332","volume":"13","author":"CH Hsueh","year":"2016","unstructured":"Hsueh CH, Yoshida K, Zhao P, Meyer TW, Zhang L, Huang SM, Giacomini KM. Identification and quantitative assessment of uremic solutes as inhibitors of renal organic anion transporters, OAT1 and OAT3. Mol Pharm. 2016;13(9):3130\u201340. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00332. (Epub 2016 Aug 9).","journal-title":"Mol Pharm"},{"key":"1469_CR45","unstructured":"PK-Sim Documentation. https:\/\/docs.open-systems-pharmacology.org\/working-with-pk-sim\/pk-sim-documentation. Accessed 25 Sep 2023."},{"issue":"2","key":"1469_CR46","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1128\/AAC.15.2.273","volume":"15","author":"HC Neu","year":"1979","unstructured":"Neu HC, Aswapokee N, Aswapokee P, Fu KP. HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1979;15(2):273\u201381. https:\/\/doi.org\/10.1128\/AAC.15.2.273.","journal-title":"Antimicrob Agents Chemother"},{"key":"1469_CR47","unstructured":"DrugBank. https:\/\/go.drugbank.com\/drugs\/DB00493. Accessed 10 Apr 2023."},{"key":"1469_CR48","unstructured":"PubChem. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/5742673. Accessed 10 Apr 2023."},{"issue":"3\u20134","key":"1469_CR49","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jpba.2005.04.033","volume":"39","author":"M Aleksi\u0107","year":"2005","unstructured":"Aleksi\u0107 M, Savi\u0107 V, Popovi\u0107 G, Buri\u0107 N, Kapetanovi\u0107 V. Acidity constants of cefetamet, cefotaxime and ceftriaxone; the effect of the substituent at C3 position. J Pharm Biomed Anal. 2005;39(3\u20134):752\u20136. https:\/\/doi.org\/10.1016\/j.jpba.2005.04.033.","journal-title":"J Pharm Biomed Anal"},{"issue":"9","key":"1469_CR50","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1002\/jps.23581","volume":"102","author":"SW Yee","year":"2013","unstructured":"Yee SW, Nguyen AN, Brown C, Savic RM, Zhang Y, Castro RA, Cropp CD, Choi JH, Singh D, Tahara H, Stocker SL, Huang Y, Brett CM, Giacomini KM. Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8). J Pharm Sci. 2013;102(9):3451\u20137. https:\/\/doi.org\/10.1002\/jps.23581. (Epub 2013 May 6).","journal-title":"J Pharm Sci"},{"issue":"14","key":"1469_CR51","doi-asserted-by":"publisher","first-page":"1126714","DOI":"10.3389\/fphar.2023.1126714","volume":"7","author":"G Deng","year":"2023","unstructured":"Deng G, Yang F, Sun N, Liang D, Cen A, Zhang C, Ni S. Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals. Front Pharmacol. 2023;7(14):1126714. https:\/\/doi.org\/10.3389\/fphar.2023.1126714.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1469_CR52","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40262-016-0475-3","volume":"56","author":"C Radke","year":"2017","unstructured":"Radke C, Horn D, Lanckohr C, Ellger B, Meyer M, Eissing T, Hempel G. Development of a physiologically based pharmacokinetic modelling approach to predict the pharmacokinetics of vancomycin in critically ill septic patients. Clin Pharmacokinet. 2017;56(7):759\u201379. https:\/\/doi.org\/10.1007\/s40262-016-0475-3.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 2","key":"1469_CR53","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2165\/00003495-198800352-00038","volume":"35","author":"F Iwabuchi","year":"1988","unstructured":"Iwabuchi F, Shimada A, Nagura Y, Takahashi S, Hatano M. Influence of cefotaxime on renal function during the treatment of infections. Drugs. 1988;35(Suppl 2):181\u20134. https:\/\/doi.org\/10.2165\/00003495-198800352-00038.","journal-title":"Drugs"},{"issue":"5","key":"1469_CR54","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/j.1552-4604.1990.tb03476.x","volume":"30","author":"HC Neu","year":"1990","unstructured":"Neu HC. Third generation cephalosporins: safety profiles after 10 years of clinical use. J Clin Pharmacol. 1990;30(5):396\u2013403. https:\/\/doi.org\/10.1002\/j.1552-4604.1990.tb03476.x.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1469_CR55","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1179\/joc.2001.13.5.461","volume":"13","author":"V Fanos","year":"2001","unstructured":"Fanos V, Cataldi L. Renal transport of antibiotics and nephrotoxicity: a review. J Chemother. 2001;13(5):461\u201372. https:\/\/doi.org\/10.1179\/joc.2001.13.5.461.","journal-title":"J Chemother"},{"issue":"6","key":"1469_CR56","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s004670050386","volume":"11","author":"BM Tune","year":"1997","unstructured":"Tune BM. Nephrotoxicity of beta-lactam antibiotics: mechanisms and strategies for prevention. Pediatr Nephrol. 1997;11(6):768\u201372. https:\/\/doi.org\/10.1007\/s004670050386.","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"1469_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.41","volume":"2","author":"H Jones","year":"2013","unstructured":"Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol. 2013;2(8): e63. https:\/\/doi.org\/10.1038\/psp.2013.41.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1469_CR58","doi-asserted-by":"publisher","unstructured":"Kumar AR, Prasad B, Bhatt DK, Mathialagan S, Varma MVS, Unadkat JD. In vivo-to-in vitro extrapolation of transporter-mediated renal clearance: relative expression factor versus relative activity factor approach. Drug Metab Dispos. 2020;49(6):470-478. https:\/\/doi.org\/10.1124\/dmd.121.000367. (Epub 2021 Apr 6. Erratum in: Drug Metab Dispos. 2021 Sep;49(9):869).","DOI":"10.1124\/dmd.121.000367"},{"issue":"9","key":"1469_CR59","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/psp4.12321","volume":"7","author":"W Huang","year":"2018","unstructured":"Huang W, Isoherranen N. Development of a dynamic physiologically based mechanistic kidney model to predict renal clearance. CPT Pharmacometrics Syst Pharmacol. 2018;7(9):593\u2013602. https:\/\/doi.org\/10.1002\/psp4.12321. (Epub 2018 Aug 11).","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"1469_CR60","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/bcp.12234","volume":"79","author":"N Tsamandouras","year":"2015","unstructured":"Tsamandouras N, Rostami-Hodjegan A, Aarons L. Combining the \u201cbottom up\u201d and \u201ctop down\u201d approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol. 2015;79(1):48\u201355. https:\/\/doi.org\/10.1111\/bcp.12234.","journal-title":"Br J Clin Pharmacol"},{"issue":"1\u20132","key":"1469_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0014-2999(03)01381-5","volume":"465","author":"S Khamdang","year":"2003","unstructured":"Khamdang S, Takeda M, Babu E, Noshiro R, Onozato ML, Tojo A, Enomoto A, Huang XL, Narikawa S, Anzai N, Piyachaturawat P, Endou H. Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. Eur J Pharmacol. 2003;465(1\u20132):1\u20137. https:\/\/doi.org\/10.1016\/s0014-2999(03)01381-5.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1469_CR62","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1248\/bpb.34.389","volume":"34","author":"H Yamaguchi","year":"2011","unstructured":"Yamaguchi H, Takeuchi T, Okada M, Kobayashi M, Unno M, Abe T, Goto J, Hishinuma T, Shimada M, Mano N. Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389\u201395. https:\/\/doi.org\/10.1248\/bpb.34.389.","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"1469_CR63","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000238596","volume":"34","author":"PA Miglioli","year":"1988","unstructured":"Miglioli PA, Tedeschi U. Importance of the mode of intravenous administration on cephotaxime concentration in bile. A comparison of bolus, drip infusion and bolus plus drip infusion. Chemotherapy. 1988;34(5):380\u20134. https:\/\/doi.org\/10.1159\/000238596.","journal-title":"Chemotherapy"},{"issue":"9","key":"1469_CR64","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1124\/dmd.114.058099","volume":"42","author":"K Abduljalil","year":"2014","unstructured":"Abduljalil K, Cain T, Humphries H, Rostami-Hodjegan A. Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. Drug Metab Dispos. 2014;42(9):1478\u201384. https:\/\/doi.org\/10.1124\/dmd.114.058099. (Epub 2014 Jul 2).","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1469_CR65","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2165\/00003088-199222030-00002","volume":"22","author":"WL St Peter","year":"1992","unstructured":"St Peter WL, Redic-Kill KA, Halstenson CE. Clinical pharmacokinetics of antibiotics in patients with impaired renal function. Clin Pharmacokinet. 1992;22(3):169\u2013210. https:\/\/doi.org\/10.2165\/00003088-199222030-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"1\u20132","key":"1469_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.05.010","volume":"109","author":"H Sun","year":"2006","unstructured":"Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006;109(1\u20132):1\u201311. https:\/\/doi.org\/10.1016\/j.pharmthera.2005.05.010. (Epub 2005 Aug 8).","journal-title":"Pharmacol Ther"},{"issue":"5","key":"1469_CR67","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1124\/dmd.117.079558","volume":"46","author":"KE Follman","year":"2018","unstructured":"Follman KE, Morris ME. Prediction of the effects of renal impairment on clearance for organic cation drugs that undergo renal secretion: a simulation-based study. Drug Metab Dispos. 2018;46(5):758\u201369. https:\/\/doi.org\/10.1124\/dmd.117.079558. (Epub 2018 Feb 28).","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1469_CR68","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/cpt.750","volume":"103","author":"CH Hsueh","year":"2018","unstructured":"Hsueh CH, Hsu V, Zhao P, Zhang L, Giacomini KM, Huang SM. PBPK modeling of the effect of reduced kidney function on the pharmacokinetics of drugs excreted renally by organic anion transporters. Clin Pharmacol Ther. 2018;103(3):485\u201392. https:\/\/doi.org\/10.1002\/cpt.750. (Epub 2017 Jul 24).","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1469_CR69","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1681\/ASN.V891470","volume":"8","author":"NS Bricker","year":"1997","unstructured":"Bricker NS, Morrin PA, Kime SW Jr. The pathologic physiology of chronic Bright\u2019s disease. An exposition of the \u201cintact nephron hypothesis.\u201d J Am Soc Nephrol. 1997;8(9):1470\u20136. https:\/\/doi.org\/10.1681\/ASN.V891470.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1469_CR70","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/cts.12481","volume":"10","author":"A Chapron","year":"2017","unstructured":"Chapron A, Shen DD, Kestenbaum BR, Robinson-Cohen C, Himmelfarb J, Yeung CK. Does secretory clearance follow glomerular filtration rate in chronic kidney diseases? Reconsidering the intact nephron hypothesis. Clin Transl Sci. 2017;10(5):395\u2013403. https:\/\/doi.org\/10.1111\/cts.12481. (Epub 2017 Jul 4).","journal-title":"Clin Transl Sci"},{"issue":"3","key":"1469_CR71","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/cpt.2642","volume":"112","author":"SPF Tan","year":"2022","unstructured":"Tan SPF, Scotcher D, Rostami-Hodjegan A, Galetin A. Effect of chronic kidney disease on the renal secretion via organic anion transporters 1\/3: implications for physiologically-based pharmacokinetic modeling and dose adjustment. Clin Pharmacol Ther. 2022;112(3):643\u201352. https:\/\/doi.org\/10.1002\/cpt.2642. (Epub 2022 Jun 13).","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1469_CR72","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1124\/dmd.114.059618","volume":"43","author":"MM Posada","year":"2015","unstructured":"Posada MM, Bacon JA, Schneck KB, Tirona RG, Kim RB, Higgins JW, Pak YA, Hall SD, Hillgren KM. Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling. Drug Metab Dispos. 2015;43(3):325\u201334. https:\/\/doi.org\/10.1124\/dmd.114.059618. (Epub 2014 Dec 12).","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"1469_CR73","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/psp4.12553","volume":"9","author":"W Huang","year":"2020","unstructured":"Huang W, Isoherranen N. Novel mechanistic PBPK model to predict renal clearance in varying stages of CKD by incorporating tubular adaptation and dynamic passive reabsorption. CPT Pharmacometrics Syst Pharmacol. 2020;9(10):571\u201383. https:\/\/doi.org\/10.1002\/psp4.12553. (Epub 2020 Sep 25).","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"1469_CR74","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s40262-020-00896-w","volume":"59","author":"N Hanke","year":"2020","unstructured":"Hanke N, T\u00fcrk D, Selzer D, Ishiguro N, Ebner T, Wiebe S, M\u00fcller F, Stopfer P, Nock V, Lehr T. A comprehensive whole-body physiologically based pharmacokinetic drug\u2013drug\u2013gene interaction model of metformin and cimetidine in healthy adults and renally impaired individuals. Clin Pharmacokinet. 2020;59(11):1419\u201331. https:\/\/doi.org\/10.1007\/s40262-020-00896-w.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 3","key":"1469_CR75","doi-asserted-by":"publisher","first-page":"S305","DOI":"10.1007\/BF01639601","volume":"8","author":"OS Nielsen","year":"1980","unstructured":"Nielsen OS, Toothaker RD, Bundtzen RW, Craig WA, Welling PG, Madsen PO. Cefotaxime pharmacokinetics following a single intravenous dose to patients with varying renal function. Infection. 1980;8(Suppl 3):S305\u20139. https:\/\/doi.org\/10.1007\/BF01639601.","journal-title":"Infection"},{"issue":"4","key":"1469_CR76","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1053\/j.ajkd.2011.12.009","volume":"59","author":"L Li","year":"2012","unstructured":"Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS, Toto RD, Wang X, Wright JT Jr, Greene TH. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis. 2012;59(4):504\u201312. https:\/\/doi.org\/10.1053\/j.ajkd.2011.12.009. (Epub 2012 Jan 26).","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1469_CR77","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1152\/physiol.00052.2018","volume":"34","author":"H Fattah","year":"2019","unstructured":"Fattah H, Layton A, Vallon V. How do kidneys adapt to a deficit or loss in nephron number? Physiology (Bethesda). 2019;34(3):189\u201397. https:\/\/doi.org\/10.1152\/physiol.00052.2018.","journal-title":"Physiology (Bethesda)"},{"issue":"10","key":"1469_CR78","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/00498254.2021.1964044","volume":"51","author":"U Fagerholm","year":"2021","unstructured":"Fagerholm U, Spjuth O, Hellberg S. Comparison between lab variability and in silico prediction errors for the unbound fraction of drugs in human plasma. Xenobiotica. 2021;51(10):1095\u2013100. https:\/\/doi.org\/10.1080\/00498254.2021.1964044. (Epub 2021 Aug 13).","journal-title":"Xenobiotica"},{"issue":"1","key":"1469_CR79","first-page":"3","volume":"70","author":"E Rutkowska","year":"2013","unstructured":"Rutkowska E, Pajak K, J\u00f3\u017awiak K. Lipophilicity\u2014methods of determination and its role in medicinal chemistry. Acta Pol Pharm. 2013;70(1):3\u201318.","journal-title":"Acta Pol Pharm"},{"issue":"1","key":"1469_CR80","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/jcm12010375","volume":"12","author":"F Turgut","year":"2023","unstructured":"Turgut F, Awad AS, Abdel-Rahman EM. Acute kidney injury: medical causes and pathogenesis. J Clin Med. 2023;12(1):375. https:\/\/doi.org\/10.3390\/jcm12010375.","journal-title":"J Clin Med"},{"issue":"2","key":"1469_CR81","first-page":"85","volume":"37","author":"K Makris","year":"2016","unstructured":"Makris K, Spanou L. Acute kidney injury: definition, pathophysiology and clinical phenotypes. Clin Biochem Rev. 2016;37(2):85\u201398.","journal-title":"Clin Biochem Rev"},{"issue":"1","key":"1469_CR82","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/healthcare7010010","volume":"7","author":"VE Blanco","year":"2019","unstructured":"Blanco VE, Hernandorena CV, Scibona P, Belloso W, Musso CG. Acute kidney injury pharmacokinetic changes and its impact on drug prescription. Healthcare (Basel). 2019;7(1):10. https:\/\/doi.org\/10.3390\/healthcare7010010.","journal-title":"Healthcare (Basel)."},{"issue":"3","key":"1469_CR83","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000446448","volume":"134","author":"V Vallon","year":"2016","unstructured":"Vallon V. Tubular transport in acute kidney injury: relevance for diagnosis, prognosis and intervention. Nephron. 2016;134(3):160\u20136. https:\/\/doi.org\/10.1159\/000446448. (Epub 2016 May 31).","journal-title":"Nephron"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01469-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01469-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01469-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T13:47:12Z","timestamp":1748008032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01469-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1469"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01469-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"9 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to include the Supplementary material.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data from patients in the ICU from a previous study were approved by the ethics committee \u201cComit\u00e9 de Protection des Personnes Sud-Est I\u201d (ref 2017-A01446-47).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consent to publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data will be made available, on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The PK-Sim\u00ae project was exported to a snapshot that is shared as a supplementary file in JSON format (Cefotaxime_Healthy_CKD.json) and enables importation of the project in PK-Sim\u00ae.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Data collection and analysis were performed by Fatima Zbib, Anthea Deschamps, and Romain Guilhaumou. Model development was performed by Fatima Zbib under the supervision of Florence Gattacceca. Suggestions for model improvement were made by all authors. The first draft of the manuscript was written by Fatima Zbib, and all authors contributed to intermediate versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}